Lagier et al., Travel Med. Infect. Dis. 101791, Jun 25, 2020,
doi:10.1016/j.tmaid.2020.101791 (Peer Reviewed)
Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis
Early treatment leads to significantly better clinical outcome and faster viral load reduction. Matched sample mortality HR 0.41 p-value 0.048. Retrospective 3,737 patients. This study includes both outpatients and hospitalized patients.
Lagier et al., 6/25/2020, retrospective, France, Europe, peer-reviewed, 22 authors, dosage 200mg tid days 1-10.
risk of death, 59.0% lower, RR 0.41, p = 0.05, treatment 35 of 3119 (1.1%), control 58 of 618 (9.4%), adjusted per study.
Effect extraction follows
pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.